Payment overview · 2025
General Payments
$804.71
32 reported records · 14 companies
Healthcare provider profile · identity verified
James L Miller, DO
Allopathic & Osteopathic Physicians|Family Medicine · BUTLER, MO · NPI 1568443935
Verified facts
What the public records show
CMS Open Payments records show James L Miller, DO received $804.71 in general payments during 2025 across 32 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $183.90 | 22.9% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $111.13 | 13.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.12 | 11.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.69 | 10.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.32 | 8.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.23 | 7.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $45.07 | 5.6% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $34.93 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.78 | 4.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.23 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.92 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.00 | 2.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.69 | 2.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.70 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $804.71 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $203.82 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $111.13 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $94.12 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.32 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.23 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $34.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
263 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1400 | 230 |
| Potassium Chloride | Potassium Chloride | 838 | 163 |
| Omeprazole | Omeprazole | 810 | 172 |
| Gabapentin | Gabapentin | 669 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 135 |
| Furosemide | Furosemide | 654 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 637 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 589 | 97 |
| Tramadol Hcl | Tramadol Hcl | 526 | 117 |
| Lisinopril | Lisinopril | 510 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 445 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 426 | 84 |
| Trazodone Hcl | Trazodone Hcl | 391 | 69 |
| Meloxicam | Meloxicam | 370 | 79 |
| Glipizide Er | Glipizide | 365 | 68 |
| Sertraline Hcl | Sertraline Hcl | 353 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 321 | 53 |
| Alprazolam | Alprazolam | 318 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 315 | 80 |
| Alendronate Sodium | Alendronate Sodium | 311 | 58 |
| Losartan Potassium | Losartan Potassium | 309 | 67 |
| Metformin Hcl | Metformin Hcl | 307 | 66 |
| Simvastatin | Simvastatin | 273 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 70 |
| Eliquis | Apixaban | 263 | 27 |
| Buspirone Hcl | Buspirone Hcl | 260 | 57 |
| Allopurinol | Allopurinol | 259 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 248 | 35 |
| Montelukast Sodium | Montelukast Sodium | 240 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 221 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 45 |
| Methylprednisolone | Methylprednisolone | 207 | 149 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 42 |
| Xarelto | Rivaroxaban | 177 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 46 |
| Donepezil Hcl | Donepezil Hcl | 169 | 26 |
| Temazepam | Temazepam | 169 | 27 |
| Azithromycin | Azithromycin | 168 | 116 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 166 | 110 |
| Lovastatin | Lovastatin | 163 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 160 | 111 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 146 | 61 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 142 | 31 |
| Finasteride | Finasteride | 139 | 29 |
| Ozempic | Semaglutide | 138 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 26 |
| Pregabalin | Pregabalin | 123 | 18 |
| Prednisone | Prednisone | 120 | 33 |
| Carvedilol | Carvedilol | 116 | 29 |
| Lorazepam | Lorazepam | 115 | 29 |
| Mupirocin | Mupirocin | 114 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 31 |
| Spironolactone | Spironolactone | 108 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 17 |
| Baclofen | Baclofen | 106 | 20 |
| Jardiance | Empagliflozin | 105 | 20 |
| Famotidine | Famotidine | 94 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 94 | 91 |
| Warfarin Sodium | Warfarin Sodium | 84 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 83 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 13 |
| Metformin Hcl Er | Metformin Hcl | 77 | 19 |
| Mirtazapine | Mirtazapine | 77 | 13 |
| Farxiga | Dapagliflozin Propanediol | 76 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 23 |
| Bupropion Xl | Bupropion Hcl | 71 | suppressed |
| Nystatin | Nystatin | 71 | 32 |
| Topiramate | Topiramate | 70 | 13 |
| Torsemide | Torsemide | 69 | 18 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | suppressed |
| Glipizide | Glipizide | 64 | 16 |
| Cephalexin | Cephalexin | 63 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 61 | suppressed |
| Clonazepam | Clonazepam | 60 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Ezetimibe | Ezetimibe | 58 | 13 |
| Ibuprofen | Ibuprofen | 58 | 13 |
| Divalproex Sodium | Divalproex Sodium | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 12 |
| Diazepam | Diazepam | 55 | 12 |
| Ondansetron Odt | Ondansetron | 55 | 37 |
| Celecoxib | Celecoxib | 53 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Primidone | Primidone | 53 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 38 |
| Ketoconazole | Ketoconazole | 51 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 20 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 12 |
| Atenolol | Atenolol | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Amoxicillin | Amoxicillin | 31 | 19 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Cinryze | C1 Esterase Inhibitor | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Topamax | Topiramate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Water | Water For Irrigation,sterile | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $804.71 · 32 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, FANAPT, JARDIANCE, JOURNAVX, NURTEC ODT, QULIPTA, REXULTI, SMARTVEST, TAKHZYRO, TRIATHLON, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error